FAP and melanoma: For example, the FAP inhibitor talabostat/BXCL701 [242] has been used in a phase II trial as a single agent for patients with metastatic colorectal cancer [242] or in association with cisplatin in melanoma [243] and is currently tested in association with anti-PD-1 therapy in advance solid cancers (NCT04171219).